SU5416, 50 mg

A broad-spectrum inhibitor of receptor tyrosine kinases, SU5416 is described by the manufacturer as targeting FLK1/KDR, RET, FLT3, and ABL. Third-party product data describe SU5416 as an ATP-competitive inhibitor of the kinase insert domain (KDR/VEGFR2/FLK1) and report activity against PDGFR, KIT, RET, FLT-3, ABL, and ALK, while noting that the compound does not inhibit EGFR or FGFR tyrosine kinases. According to the same data, the reported IC₅₀ values are 1 μM for KDR, 20 μM for PDGFR, 30 nM for KIT, 170 nM for RET, 160 nM for FLT-3, 11 μM for ABL, and 1.2 μM for ALK. In published research, SU5416 has been used to prevent angiogenesis and inhibit tumor growth and vascularization in cancer models, to induce pulmonary hypertension in the SuHx rat model of pulmonary arterial hypertension when combined with hypoxia, and to inhibit TGFβ1 activation and delay wound healing in rats. Alternative names for the compound include Semaxinib, Sugen 5416, and VEGFR 2 Kinase Inhibitor. The product is supplied by STEMCELL Technologies with a reported purity of ≥ 98% and a molecular weight of 238.3 g/mol.